Visit the Kratom Roundtable
2nd CRE Letter to the DEA (September 12, 2016)
1sr CRE Letter to the DEA (September 8, 2016)
CRE has submitted a Request for Information to DEA regarding its listing of kratom as a Schedule I narcotic. The information so requested is the DEA letter to HHS as mentioned in the Federal Register which announced the aforementioned listing, which states:
The Administrator [DEA} transmitted notice of his intent to place mitragynine and 7-hydroxymitragynine in schedule I on a temporary basis to the Assistant Secretary[HHS] by letter dated May 6, 2016.
The information contained in the DEA letter to HHS is of critical importance in assessing the merits of the agency’s science. CRE was surprised that the said letter is not immediately accessible on the DEA website nor was it made available in the DEA listing of kratom as a Schedule I narcotic as noted in the Federal Register notice.
In that federal regulators review CRE websites, CRE recommends that interested parties increase their leverage by broadcasting this post to other stakeholders.
Please see cre-letter-to-dea-officials